Avadel Pharmaceuticals plc (NASDAQ:AVDL) has a beta value of 1.36 and has seen 1.58 million shares traded in the last trading session. The AVDL stock price is -63.72% off its 52-week high price of $19.09 and 10.72% above the 52-week low of $10.41. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.22 million shares traded. The 3-month trading volume is 1.12 million shares.
The consensus among analysts is that Avadel Pharmaceuticals plc (AVDL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 8 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.04.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
Over the past 30 days, the shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) have changed -10.31%. Short interest in the company has seen 9.45 million shares shorted with days to cover at 11.17.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 2.83% from current levels. The projected low price target is $9.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -157.29% off the targeted high while a plunge would see the stock lose 22.81% from current levels.
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
Figures show that Avadel Pharmaceuticals plc shares have outperformed across the wider relevant industry. The company’s shares have lost -25.97% over the past 6 months, with this year growth rate of 76.00%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be 512.99%.
8 analysts offering their estimates for the company have set an average revenue estimate of 52.7M for the current quarter. 6 have an estimated revenue figure of 58.71M for the next ending quarter. Year-ago sales stood 19.45M and 27.18M respectively for this quarter and the next, and analysts expect sales will grow by 170.89% for the current quarter and 512.99% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.78% over the past 5 years. Earnings growth for 2024 is a modest 76.06% while over the next 5 years, the company’s earnings are expected to increase by 15.00%.
AVDL Dividends
Avadel Pharmaceuticals plc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders
Insiders own 4.77% of the company shares, while shares held by institutions stand at 80.07% with a share float percentage of 84.08%. Investors are also buoyed by the number of investors in a company, with Avadel Pharmaceuticals plc having a total of 231.0 institutions that hold shares in the company. The top two institutional holders are VIVO CAPITAL, LLC with over 3.97 million shares worth more than $55.85 million. As of 2024-06-30, VIVO CAPITAL, LLC held 4.332% of shares outstanding.
The other major institutional holder is TRI LOCUM PARTNERS LP, with the holding of over 1.19 million shares as of 2024-06-30. The firm’s total holdings are worth over $16.72 million and represent 1.2973% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Janus Henderson Global Life Sciences Fund . As of Jun 30, 2024 , the former fund manager holds about 3.10% shares in the company for having 2.98 shares of worth $34.78 million while later fund manager owns 2.67 shares of worth $31.17 million as of Sep 30, 2024 , which makes it owner of about 2.77% of company’s outstanding stock.
